Wednesday, March 18, 2009

BIO Applauds Bipartisan FOBs Bill

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement regarding H.R. 1548, the Pathway to Biosimilars Act, introduced today by Representatives Anna Eshoo (D-CA), Jay Inslee (D-WA) and Joe Barton (R-TX) that would develop a regulatory pathway for approving biosimilars, medicines which are similar to pioneering biomedical therapies and treatments:

“The legislation introduced today by Representatives Eshoo, Inslee and Barton bill lays out an effective, reasonable and safe pathway to biosimilars. It is the right medicine for lowering costs, ensuring patient safety and providing fair, responsible incentives for continued biotech research into cures for diseases such as cancer, multiple sclerosis, Alzheimer’s and HIV/AIDS. In short, the bill provides patients with the right balance between innovation and competition.

“This bill will lead to real solutions for our nation’s health care challenges and provide real hope for patients. It will help reduce costs by enabling additional competition among biologics but at the same time help safeguard patient safety by requiring demonstration of the purity, safety and effectiveness of biosimilars. More, the bill includes the incentives necessary for biotechnology researchers to develop new breakthrough therapies and potential cures.

“The Eshoo-Inslee-Barton bill establishes parity with the outcomes of the Hatch-Waxman regime developed for traditional pharmaceuticals, balancing the need to increase access, lower costs, ensure drug safety and promote continued biomedical breakthroughs. At the same time, the bill recognizes the fundamental differences between biologics and traditional pharmaceuticals. Traditional pharmaceuticals are produced by machines and are relatively simple for generics makers to copy. Innovative biologics, on the other hand, are grown from living cells and are so molecularly complex that current science does not allow for an exact copy to be made, as the Food and Drug Administration (FDA) has recognized. The fact that the medications are different calls for a slightly different set of rules around safety and competition incentives to achieve the same goals.

“BIO commends Reps. Eshoo, Inslee and Barton for their continued efforts to establish a pathway for the development and approval of biosimilars. We are pleased to join them, their 35 additional Congressional co-sponsors, and a diverse array of patient, physician and other organizations in announcing our support for this legislation. We look forward to working with the Congress as they consider this balanced, landmark bill.”

No comments: